Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc

Table 1 Residual entry of selected HIV-1 subtype C Envs in the presence of MVC in NP2-CD4/CCR5 and 293-Affinofile CD4^med/CCR5^hi cells

Patient ID	Env clone	Residual entry in NP2 cells (%)^a	Residual entry in Affinofile cells (%)^a
	ADA	0.25 ± 0.04	n.a.
	YU2	0.04 ± 0.02	0.26 ± 0.02
	JRCSF	0.09 ± 0.02	0.18 ± 0.02
	MVCres	37.8 ± 1.01	68.45 ± 14.35
	MVCsens	1.82 ± 0.2	47.28 ± 2.23
204	E-7	3.6 ± 0.09	36.24 ± 5.01
550	I-2	3.80 ± 0.71	52.6 ± 13.87
	I-7	3.84 ± 1.00	36.2 ± 1.81
	F-12	4.32 ± 1.32	60.32 ± 7.20
	F-20	2.80 ± 1.11	38.83 ± 4.09
1375	E-2	9.73 ± 2.50	84.20 ± 8.99
1375	I-8	20.34 ± 5.23	69.03 ± 9.10
1441	E-1	5.70 ± 0.47	44.77 ± 2.55
	E-2	2.7 ± 1.00	53.69 ± 9.14
	E-6	6.72 ± 0.66	67.26 ± 9.58
	I-2	3.90 ± 0.49	68.34 ± 11.52
	I-9	4.57 ± 0.42	79.78 ± 4.18
1503	F-7	3.37 ± 0.71	n.a.
1684	E-7	2.84 ± 1.74	27.46 ± 3.51
1854	I-7	4.56 ± 0.73	n.a.
2042	I-38	2.95 ± 0.86	38.77 ± 0.53

ISSN: 1742-4690